Background Currently used antiplatelet drugs, including aspirin, ticlopidine, and others, are effective against certain but not all of the many endogenous platelet activators. Because of their limited efficacy, a significant number of serious thromboembolic complications still occur, highlighting the need for a more effective therapy. Thus, we have identified a systemically active peptide analogue (DMP 728) of the arginine-glycine-aspartic acid (RGD) recognition sequence that mediates the binding of ligands such as fibrinogen to the platelet glycoprotein (GP) IIb/I11a receptors. The goals of the present study were to determine the antiplatelet and antithrombotic efficacies of DMP 728 in various arterial thrombosis models.
Methods and Results DMP 728 demonstrated antiplatelet efficacy in vitro in inhibiting ADP-induced human platelet aggregation (IC_%, 46+2 nmol/L) and fibrinogen binding to human platelets (ICn%, 2.3±0.8 nmol/L) or purified human GPIIb/IIIa receptors (IC.%, 0.6±0.1 nmol/L). DMP 728 demonstrated high affinity and specificity for human platelet GPIb/IIIa over other adhesion molecules. In anesthetized mongrel dogs, DMP 728 at 0.001 to 1.0 mg/kg IV produced dose-dependent antiplatelet effects in inhibiting ex vivo platelet aggregation induced by ADP and in prolonging template bleeding time. DMP 728 effects on bleeding time prolongation P latelet activation and the resulting aggregation have been shown to be associated with various pathological conditions, including cardiovascular and cerebrovascular thromboembolic disorders such as unstable angina, myocardial infarction, transient ischemic attack, stroke, and atherosclerosis.'-5 The contribution of platelets to these disease processes stems from their ability to form aggregates or platelet thrombi as a consequence of arterial wall injury. 6 Injury of blood vessel walls could occur either acutely or chronically by various pathophysiological processes. Platelets are then activated by a number of activators or agonists that are released from within the platelets or from the injured arterial walls, with subsequent adherence, aggregation to the disrupted vessel surface, and resultant formation of an occlusive thrombus in the lumen of the vessel. [7] [8] [9] were more rapidly reversible than those on platelet aggregation inhibition. A maximal antiplatelet effect for DMP 728 was demonstrated at 0.01 mg/kg IV bolus. The antithrombotic efficacy of DMP 728 was examined in vitro and in vivo after IV administration at different doses in various models of arterial thrombosis. In '-23 In this report, the antithrombotic efficacy of DMP 728 (Fig 1) , a low-molecular-weight novel antiplatelet agent with high affinity and specificity for the platelet GPIIb/ IlIa receptors, is described. In particular, the present study examined (26.5 ,uCilmg) was obtained from Du Pont NEN (Boston, Mass).
acid salt) and RGDS were synthesized at the DuPont Merck Pharmaceutical Co (Wilmington, Del).
Platelet Aggregation Assay
Venous blood was obtained from anesthetized mongrel dogs or from healthy human donors who were drug-and aspirinfree for at least 2 weeks before blood collection. Blood was collected into citrated Vacutainer tubes. The blood was centrifuged for 15 minutes at 150g (850 rpm in a Sorvall RT6000 tabletop centrifuge with H-1000 B rotor) at room temperature, and platelet-rich plasma (PRP) was removed. The remaining blood was centrifuged for 15 minutes at 150% (26 780 rpm) at room temperature, and platelet-poor plasma (PPP) was removed. Samples were assayed on a PAP-4 Platelet Aggregation Profiler with PPP as the blank (100% transmittance). PRP (200 ,uL) (5 x 108 platelets/mL) was added to each micro test tube, and transmittance was set to 0%. ADP (20 ,L) (10 ,umol/L) was added to each tube, and the aggregation profiles were plotted (percent transmittance versus time). DMP 728 (20 iLL) was added at different concentrations before the addition of the platelet agonist. Results are expressed as percent inhibition of agonist-induced platelet aggregation.
Platelet-Fibrinogen Binding Assay
Binding of`1I-fibrinogen to platelets was performed as described by Bennett and Vilaire,25 with some modifications as described below. Human PRP (h-PRP) was applied to a sepharose column to prepare human gel-purified platelets (h-GPP). Aliquots of h-GPP (5 x 108 platelets/mL) along with 1 mmol/L calcium chloride were added to removable 96-well plates, "11-fibrinogen (26.5 ,uCi/mg) was added, and the h-GPP were activated by addition of the previously described platelet agonists. The '21I-fibrinogen bound to the activated platelets was separated from the free form by centrifugation and then counted on a gamma counter. Nonspecific binding (due to entrapment of`'1-fibrinogen) in either the presence or absence of the inhibitors was shown to be in the range of 4% to 6% of total "1-fibrinogen binding to activated platelets.
Percent inhibition of`1I-fibrinogen binding to activated platelets was calculated by dividing the specific binding (ie, total binding minus nonspecific binding) obtained in the presence of inhibitors by that obtained in the absence of the inhibitors. For IC50 evaluation, DMP 728 was added at various concentrations before platelet activation.
Metabolism/Stability Study
The potential metabolism of DMP 728 by microsomal and nonmicrosomal enzymes obtained from various species, including rats, dogs, and humans, was determined. The metabolic effect of standard proteolytic enzymes such as pepsin, trypsin, enterokinases, proteases, and peptidases was determined as well. ['H]DMP 728 (24.3 Ci/mmol) with a chemical purity of 99% was incubated in the presence or absence of the previously described microsomal, nonmicrosomal, or proteolytic enzymes. After incubation at the optimal pH, temperature, and buffer conditions for the different enzyme systems to be tested, the [3H]DMP 728 remaining was quantified by high-performance liquid chromatography (HPLC) with on-line radiochemical detection. The metabolic viability of the different enzyme systems used was confirmed by incubating each enzyme with its known standard substrate under the same conditions as used for DMP 728. Additionally, the effects of different pHs, including 3.0, 7.4, and 8.5, on the stability of DMP 728 were examined by HPLC with UV detection. DMP 728 (100 ,g/mL) was incubated in 50 mmol/L phosphate buffer at the above pHs for up to 6 hours. After incubation, the remaining DMP 728 was quantified by HPLC with UV (210 nm) detection. 
Antiplatelet Effects in Anesthetized Dogs
Experimental Procedures. Mongrel dogs of either sex weighing between 8 and 12 kg were anesthetized by intravenous administration of pentobarbital sodium solution (30 mg/kg) (Abbott Laboratories, 50 mg/mL vial). Animals were placed on a respiratory pump (model 665, Harvard Apparatus, South Natick, Mass) with the stroke volume adjusted to the dog's weight (stroke volume=dog's weight in kilograms times 15 mL/kg), and the respirator dials were set on 20 beats per minute and 50% respiration. Both femoral arteries were cannulated, one was attached to a transducer by which heart rate and blood pressure were monitored on a chart recorder (Gould Recorder 2800S, Gould, Cleveland, Ohio) throughout the study, and the other was used for repeated blood sampling. The femoral vein was also cannulated to administer DMP 728 or vehicle and for maintenance of anesthesia as needed.
Experimental Protocol. Animals were dosed intravenously (into the cannulated femoral vein over a period of 2 minutes after a basal blood sample) with DMP 728. DMP 728 was administered at different doses (0.001 to 1.0 mg/kg IV bolus). Bleeding time was determined before and at different intervals after DMP 728. Blood samples were collected into Vacutainer tubes (4.5 mL draw, each containing 0.5 mL of 0.05 mol/L sodium citrate) before and at different intervals after administration of DMP 728. Blood samples were placed on a platform rocker until the end of the study, and the samples were then assayed for platelet aggregation, platelet counts, and DMP 728 plasma levels. Plasma levels of DMP 728 were measured by an ELISA and by HPLC with a fluorescence detection method developed in our laboratory.
Bleeding Time. 9 V, connected to a 250 000-Qt potentiometer in series). The cathode was connected to a distant subcutaneous site. The current delivered to the arterial wall was monitored continuously and maintained at 150 ,tA. Proper positioning of the electrode in the femoral artery was confirmed by visual inspection at the end of each experiment. In all experiments, the anodal current was applied for a maximum period of 3 hours. Arterial flow was monitored throughout the experiment by an electromagnetic flow probe connected to a flow meter (Carolina Medical Electronics) placed around the distal portion of the vessel segment.
Prevention of Rethrombosis After Thrombolysis
The anodal current was applied to the femoral artery for a maximum period of 3 hours or was terminated 15 minutes after blood flow in the vessel had remained stable at zero flow velocity (ie, stable occlusive thrombus formation). Then DMP 728 was administered at 1.0 mg/kg IV bolus at 30 minutes before tissue-type plasminogen activator (TPA) or streptokinase (SK). The dose regimens of the thrombolytics were as follows: TPA was administered at 0.02 mg/kg intra-arterially (loading dose), followed by intra-arterial infusion of 0.003 mg kg`min'1 until lysis occurred; SK was administered at 10 000 U/kg IV (loading dose), followed by a constant infusion at 300 U. kg-min-1 until lysis occurred. Animals were followed for 4 hours after thrombolysis. At the end of the study, the vessel segment was ligated both proximal and distal to the point of injury and removed without disturbing the intravascular thrombus. The vessel segment was opened along its length, and the intact thrombus mass was lifted off the intimal surface of the vessel. The weight of the thrombus mass was determined from an analytical balance. The protocol for this series of experiments is summarized in Fig 3. Reperfusion (Table   3) . Additionally, DMP 728 was without any effects on the different coagulation parameters, such as prothrombin time, thrombin time, or activated partial thromboplastin time (data not shown). A close correlation between the in vitro and ex vivo antiplatelet inhibitory efficacy of DMP 728 was noted based on the plasma levels (Tables 1 and 2 ). At plasma concentrations of 10 to 15 ng/mL, DMP 728 resulted in 50% to 60% inhibition of ex vivo platelet aggregation without any significant effects on bleeding time prolongation in anesthetized dogs. A maximal inhibition of ex vivo platelet aggregation along with 1.5-to 2.0-fold prolongation in bleeding time over basal values was shown at 35 to 45 ng/mL plasma levels of DMP 728 (Table 2) . In Vitro Antithrombotic Efficacy Perfusion of human blood through a mechanically injured (external clamping) isolated rabbit aorta was shown to result in CFR. DMP 728 demonstrated total prevention of CFR at 0.1 ,mol/L, with no effect on CFR at 0.01 ,umol/L. The antithrombotic effects of other standard antiplatelet agents, including aspirin and ticlopidine as well as the GPIIb/IIIa prototype antagonist RGDS, were evaluated. RGDS at 1.0 mmol/L demonstrated 100% antithrombotic efficacy in reducing CFR, compared with maximal antithrombotic efficacy with DMP 728 at 0.1 ,umol/L. In contrast, neither aspirin nor ticlopidine showed any distinct antithrombotic efficacy at concentrations up to 1.0 mmol/L (Fig  4) . Additionally, in the same model but with a ballooninduced intimal wall injury, DMP 728 maximally inhibited both platelet deposition and arterial flow reduction at 0.1 to 1.0 ,mol/L (data not shown). DMP 728 at 0.01 and 0.1 ,umol/L corresponds to 10% to 20% and 100% inhibition of in vitro human platelet aggregation, respectively. In Vivo Antithrombotic Efficacy in Dogs Coronary Artery Thrombosis in Dog (Folts Model) .
In this model of unstable angina, a platelet-dependent thrombus is produced in a mechanically injured coronary artery (LCx) in the presence of a high degree of arterial constriction.26,27 Under these conditions, coronary blood flow is occluded as a platelet-rich thrombus forms, which is followed by spontaneous dislodging of the thrombus in a cyclic manner (CFR). This study examined the antithrombotic efficacy of DMP 728 at 0.005 and 0.01 mg/kg IV bolus in this platelet-mediated thrombosis model. In 20 anesthetized dogs, arterial injury along with a high degree of stenosis of the LCx resulted in cyclic platelet-rich thrombus formation, leading to repeated CFR. In saline-treated animals (n=11), CFR of seven or eight per hour continued consistently throughout the experiment. DMP 728 at 0.005 mg/kg IV bolus (n=4) and 0.01 mg/kg IV bolus (n=5) prevented CFRs in 2 of 4 and in 5 of 5 dogs, respectively (Fig 5) . DMP 728 demonstrated both maximal antiplatelet and antithrombotic efficacies at 0.01 mg/kg IV bolus in anesthetized dogs (Table 2 and Fig  5) . The onset for the antithrombotic effects of DMP 728 was immediate, with a dose-dependent duration of action.
Femoral Artery Rethrombosis in Dogs (Electrolytic Injury Model). A total of 24 mongrel dogs, divided into four groups, were entered into this arm of the study. There were no statistically significant differences among the groups with regard to the time to occlusion ( Table 4 ). The effects of DMP 728 on the incidence of 359±32  30  98±5  >15  200±6  60  95±7  131±4  120  97±0  87±4  180  100±0  >15  21±2  360  65±11  10±3  1.0  5  100±0  4015±222  30  100±0  >15  1624±100  60  100±0  878±70  120  100±0  375±20  180  100±0  >15  230±15  360  100±0 reocclusion, time to reocclusion, time to reperfusion, canine femoral artery model were examined. DMP 728 and on thrombus weight after thrombolysis (SK or administered at 1.0 mg/kg IV bolus before adminis-TPA) of an electrolytically induced thrombus in a tration of SK or TPA resulted in total prevention of (Table 4) . A significant prolongation of the time to reocclusion to >240 minutes (ie, 100% prevention of the incidence of reocclusion for up to the maximum period of the study) was demonstrated ( Fig  6) . The 1.0 mg/kg IV bolus dose of DMP 728 administered under this protocol is a supermaximal dose, based on the in vivo antiplatelet effects and the plasma levels as shown in In the femoral artery thrombosis and rethrombosis model in dogs, DMP 728 (1.00 mg/kg IV) demonstrated maximal antithrombotic efficacy in electrolytically induced femoral artery thrombosis and rethrombosis after thrombolysis with either TPA or SK. Despite the increased thrombogenic stimulus as demonstrated in the electrolytically induced arterial thrombosis in the femoral artery, DMP 728 shortened the time to reperfusion when given in conjunction with either SK or TPA and was also capable of limiting further platelet deposition at the site of the damage. However, it remains to be determined in a clinical setting how long after thrombolysis platelet inhibition must be sustained to render injured vessel and resid- 
